

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**June 15, 2017**

Missouri Coalition for Community Behavioral Healthcare  
221 Metro Drive, Jefferson City, MO 65101

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Stephen Calloway/Mitch Ruth
10:25 - 10:35	DUR Update	Stephen Calloway

**Old Business**

10:35 – 10:40	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b>	Stephen Calloway
---------------	--	------------------

**New Business**

10:40 – 11:00	<b>B. Proposed Actions - New Drug/Product Review</b> (See website and Attached Summary) <ul style="list-style-type: none"><li><b>I. Open Access</b></li><li><b>II. Clinical Edit/Step Therapy</b></li><li><b>III. PDL Products</b></li><li><b>IV. Prior Authorization</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	Stephen Calloway
---------------	--	------------------

11:00 – 11:45	<b>C. Clinical Edits</b> <ul style="list-style-type: none"><li><b>I. Exondys 51 Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>II. Spinraza Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li><li><b>III. Short-Acting (Single-Agent) Opioid Clinical Edit</b><ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul></li></ul>	
---------------	--	--

**D. Preferred Drug List (PDL)**

- I. Amylin Analogs**
  - Discussion
  - Public Hearing
  - Decision
- II. Antihyperuricemic Agents**
  - Discussion
  - Public Hearing
  - Decision
- III. Bile Salts Agents**
  - Discussion
  - Public Hearing
  - Decision
- IV. Bone Deossification Suppression Agents (including Calcitonin)**
  - Discussion
  - Public Hearing
  - Decision
- V. BPH Agents (formerly Androgen Hormone Inhibitors)**
  - Discussion
  - Public Hearing
  - Decision
- VI. Cephalosporins and Related Antibiotics - Oral**
  - Discussion
  - Public Hearing
  - Decision
- VII. Cryopyrin-Associated Periodic Syndrome (CAPS) Agents**
  - Discussion
  - Public Hearing
  - Decision
- VIII. DPP-IV (Dipeptidyl Peptidase-4) Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- IX. Electrolyte Depleters (Phosphate Binders)**
  - Discussion
  - Public Hearing
  - Decision
- X. Fluoroquinolones – Oral**
  - Discussion
  - Public Hearing
  - Decision

- XI. GI Antibiotics – Oral:**
  - Discussion
  - Public Hearing
  - Decision
- XII. GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)**
  - Discussion
  - Public Hearing
  - Decision
- XIII. Growth Hormones and Growth Factors**
  - Discussion
  - Public Hearing
  - Decision
- XIV. Hematopoietic Agents**
  - Discussion
  - Public Hearing
  - Decision
- XV. Insulins**
  - Discussion
  - Public Hearing
  - Decision
- XVI. Insulins – Long Acting**
  - Discussion
  - Public Hearing
  - Decision
- XVII. Insulins – Mix**
  - Discussion
  - Public Hearing
  - Decision
- XVIII. Insulins – Rapid Acting**
  - Discussion
  - Public Hearing
  - Decision
- XIX. Intravaginal Antibiotics**
  - Discussion
  - Public Hearing
  - Decision
- XX. Macrolides – Adult**
  - Discussion
  - Public Hearing
  - Decision

- XXI. Macrolides – Pediatric**
  - Discussion
  - Public Hearing
  - Decision
- XXII. Methotrexate Products – Oral and Injectable**
  - Discussion
  - Public Hearing
  - Decision
- XXIII. Multiple Sclerosis (MS) Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXIV. Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- XXV. Oral Anti-Diabetics: Biguanides**
  - Discussion
  - Public Hearing
  - Decision
- XXVI. Oral Anti-Diabetics: Combinations**
  - Discussion
  - Public Hearing
  - Decision
- XXVII. Oral Anti-Diabetics: Meglitinides**
  - Discussion
  - Public Hearing
  - Decision
- XXVIII. Oral Anti-Diabetics: Sulfonylureas 2<sup>nd</sup> Generation**
  - Discussion
  - Public Hearing
  - Decision
- XXIX. Oral Anti-Diabetics: Thiazolidinediones**
  - Discussion
  - Public Hearing
  - Decision
- XXX. Penicillins**
  - Discussion
  - Public Hearing
  - Decision

**XXXI. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors**

- Discussion
- Public Hearing
- Decision

**XXXII. Targeted Immune Modulators (formerly Biologics – Disease Modifying Anti-Rheumatic Drugs- DMARDs)**

- Discussion
- Public Hearing
- Decision

**XXXIII. Tetracyclines**

- Discussion
- Public Hearing
- Decision

**XXXIV. Urinary Tract Antispasmodics**

- Discussion
- Public Hearing
- Decision

**E. Preferred Drug List Classes for Sept/Oct**

- I. Process Discussion
- II. Therapeutic classes/to be announced at meeting

1:00

**LUNCH**

1:15-1:30

**Program Utilization Information-Xerox Update**

Luke Boehmer

1:30-1:50

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: September 21, 2017**

**Department of Natural Resources**

**La charrette/Nightengale Rooms**

**1101 Riverside Dr.**

**Jefferson City, MO 65101**